Fuji Pharma Co Ltd 2023 IR
The report outlines Fuji Pharma Co., Ltd.'s business activities, financial performance, and sustainability initiatives for the fiscal year ended September 30, 2022. Key highlights include the launch of F-meno_x0000_ capsules, the expansion of insurance coverage for infertility treatments, and the completion of the sixth drug production building at the Toyama Plant to triple hormone tablet capacity. In sustainability, the company endorsed the TCFD recommendations, signed an offsite solar PPA to reduce CO2 emissions, and was certified as a 2023 Health & Productivity Management Outstanding Organization. Additionally, its subsidiary OLIC in Thailand obtained approval for NEXTSTELLIS™.
Company: Fuji Pharma Co Ltd
Sector: Health Care
Country: Japan
Year: 2023
Type: IR
Pages: 29
Fuji Pharma Co Ltd
Corporate Report
The report outlines Fuji Pharma Co., Ltd.'s business activities, financial performance, and sustainability initiatives for the fiscal year ended September 30, 2022. Key highlights include the launch of F-meno_x0000_ capsules, the expansion of insurance coverage for infertility treatments, and the completion of the sixth drug production building at the Toyama Plant to triple hormone tablet capacity. In sustainability, the company endorsed the TCFD recommendations, signed an offsite solar PPA to reduce CO2 emissions, and was certified as a 2023 Health & Productivity Management Outstanding Organization. Additionally, its subsidiary OLIC in Thailand obtained approval for NEXTSTELLIS™.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Oct 1, 2021 - Sep 30, 2022
Fiscal Year
2022
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Women on Board
Women in Management
Net Zero Target
Employees